Compare CPAC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | RIGL |
|---|---|---|
| Founded | 1949 | 1996 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 884.9M |
| IPO Year | 2003 | 2000 |
| Metric | CPAC | RIGL |
|---|---|---|
| Price | $12.55 | $47.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.90 | ★ $45.67 |
| AVG Volume (30 Days) | 40.6K | ★ 231.9K |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ $19.78 | $35.77 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $6.25 | $24.84 |
| 52 Week High | $12.74 | $52.24 |
| Indicator | CPAC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 60.21 |
| Support Level | $11.56 | $40.05 |
| Resistance Level | N/A | $49.10 |
| Average True Range (ATR) | 0.26 | 1.50 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 98.25 | 51.44 |
Cementos Pacasmayo SAA is a Peruvian cement company, and only cement manufacturer serving in the northern region of Peru. It produce, distribute and sell cement and cement-related materials, such as precast products and ready-mix concrete. Its products are mainly used in construction, which has been one of the fastest growing segments of the Peruvian economy in recent years. It also produce and sell quicklime for use in mining operations. It also provide transportation services. It has three operating segments cement, concrete, mortar, pavement and precast; quicklime; and sales of construction supplies. The majority of profit comes from Cement segment. Peru's cement production is into three regions northern region, central region, including Lima's metropolitan area, and southern region.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.